188 related articles for article (PubMed ID: 25621798)
41. Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study.
Maziarz RT; Brazauskas R; Chen M; McLeod AA; Martino R; Wingard JR; Aljurf M; Battiwalla M; Dvorak CC; Geroge B; Guinan EC; Hale GA; Lazarus HM; Lee JW; Liesveld JL; Ramanathan M; Reddy V; Savani BN; Smith FO; Strasfeld L; Taplitz RA; Ustun C; Boeckh MJ; Gea-Banacloche J; Lindemans CA; Auletta JJ; Riches ML
Bone Marrow Transplant; 2017 Feb; 52(2):270-278. PubMed ID: 27991895
[TBL] [Abstract][Full Text] [Related]
42. Pre-transplant ferritin, albumin and haemoglobin are predictive of survival outcome independent of disease risk index following allogeneic stem cell transplantation.
Chee L; Tacey M; Lim B; Lim A; Szer J; Ritchie D
Bone Marrow Transplant; 2017 Jun; 52(6):870-877. PubMed ID: 28504664
[TBL] [Abstract][Full Text] [Related]
43. Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
Brammer JE; Stentz A; Gajewski J; Curtin P; Hayes-Lattin B; Kovacsovics T; Leis JF; Meyers G; Nemecek E; Subbiah N; Frires R; Palmbach G; Avraham GP; Slater S; Maziarz RT
Biol Blood Marrow Transplant; 2015 Jan; 21(1):89-96. PubMed ID: 25445641
[TBL] [Abstract][Full Text] [Related]
44. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
45. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation.
Remberger M; Svahn BM; Mattsson J; Ringdén O
Transplantation; 2004 Jul; 78(1):122-7. PubMed ID: 15257050
[TBL] [Abstract][Full Text] [Related]
46. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
47. A single centre experience with allogeneic stem cell transplantation for severe aplastic anaemia in childhood.
Ladenstein R; Peters C; Minkov M; Emminger-Schmidmeier W; Mann G; Höcker P; Hawliczek R; Rosenmayr A; Fink FM; Niederwieser D; Gadner H
Klin Padiatr; 1997; 209(4):201-8. PubMed ID: 9293451
[TBL] [Abstract][Full Text] [Related]
48. Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents with Hematologic Malignancies: An AIEOP-GITMO Retrospective Multicenter Study.
Berger M; Lanino E; Cesaro S; Zecca M; Vassallo E; Faraci M; De Bortoli M; Barat V; Prete A; Fagioli F
Biol Blood Marrow Transplant; 2016 May; 22(5):902-9. PubMed ID: 26860636
[TBL] [Abstract][Full Text] [Related]
49. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
50. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
51. Neurologic complications after allogeneic hematopoietic stem cell transplantation in children: analysis of prognostic factors.
Kang JM; Kim YJ; Kim JY; Cho EJ; Lee JH; Lee MH; Lee SH; Sung KW; Koo HH; Yoo KH
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1091-8. PubMed ID: 25708217
[TBL] [Abstract][Full Text] [Related]
52. Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.
Arai Y; Kanda J; Nakasone H; Kondo T; Uchida N; Fukuda T; Ohashi K; Kaida K; Iwato K; Eto T; Kanda Y; Nakamae H; Nagamura-Inoue T; Morishima Y; Hirokawa M; Atsuta Y; Murata M;
Bone Marrow Transplant; 2016 Jan; 51(1):96-102. PubMed ID: 26367230
[TBL] [Abstract][Full Text] [Related]
53. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
[TBL] [Abstract][Full Text] [Related]
54. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
Le Bourgeois A; Lestang E; Guillaume T; Delaunay J; Ayari S; Blin N; Clavert A; Tessoulin B; Dubruille V; Mahe B; Roland V; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Chevallier P
Eur J Haematol; 2013 Mar; 90(3):177-86. PubMed ID: 23301689
[TBL] [Abstract][Full Text] [Related]
55. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients.
Hamilton BK; Law AD; Rybicki L; Abounader D; Dabney J; Dean R; Duong HK; Gerds AT; Hanna R; Hill BT; Jagadeesh D; Kalaycio ME; Lawrence C; McLellan L; Pohlman B; Sobecks RM; Bolwell BJ; Majhail NS
Bone Marrow Transplant; 2015 Sep; 50(9):1235-40. PubMed ID: 26030045
[TBL] [Abstract][Full Text] [Related]
57. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
58. Impact of Human Herpesvirus-6 Reactivation on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation.
Aoki J; Numata A; Yamamoto E; Fujii E; Tanaka M; Kanamori H
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2017-22. PubMed ID: 26226409
[TBL] [Abstract][Full Text] [Related]
59. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
Nakamae H; Yamane T; Hasegawa T; Nakamae M; Terada Y; Hagihara K; Ohta K; Hino M
Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
[TBL] [Abstract][Full Text] [Related]
60. Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants.
Hill BT; Bolwell BJ; Rybicki L; Dean R; Kalaycio M; Pohlman B; Tench S; Sobecks R; Andresen S; Copelan E
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1738-46. PubMed ID: 20558313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
